Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42345 (
mTOR
)
26,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although hepatocellular carcinoma (HCC) is one of the most common malignancies and constitutes the third leading cause of cancer-related deaths, the underlying molecular mechanisms are not fully understood. In the present study, we demonstrate for the first time that hepatocytes express signalling lymphocytic activation molecule family member 3 (
SLAMF3
/CD229) but not other SLAMF members. We provide evidence to show that
SLAMF3
is involved in the control of hepatocyte proliferation and in hepatocellular carcinogenesis.
SLAMF3
expression is significantly lower in primary human HCC samples and HCC cell lines than in human healthy primary hepatocytes. In HCC cell lines, the restoration of high levels of
SLAMF3
expression inhibited cell proliferation and migration and enhanced apoptosis. Furthermore,
SLAMF3
expression was associated with inhibition of HCC xenograft progression in the nude mouse model. The restoration of
SLAMF3
expression levels also decreased the phosphorylation of MAPK ERK1/2, JNK and
mTOR
. In samples from resected HCC patients,
SLAMF3
expression levels were significantly lower in tumorous tissues than in peritumoral tissues. Our results identify
SLAMF3
as a specific marker of normal hepatocytes and provide evidence for its potential role in the control of proliferation of HCC cells.
...
PMID:Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression. 2437 6
Polo-like kinase PLK1 is a cell cycle protein that plays multiple roles in promoting cell cycle progression. Among the many roles, the most prominent role of PLK1 is to regulate the mitotic spindle formation checkpoint at the M-phase. Recently we reported the expression of
SLAMF3
in Hepatocytes and show that it is down regulated in tumor cells of hepatocellular carcinoma (HCC). We also show that the forced high expression level of
SLAMF3
in HCC cells controls proliferation by inhibiting the MAPK ERK/JNK and the
mTOR
pathways. In the present study, we provide evidence that the inhibitory effect of
SLAMF3
on HCC proliferation occurs through Retinoblastoma (RB) factor and PLK1-dependent pathway. In addition to the inhibition of MAPK ERK/JNK and the
mTOR
pathways, expression of
SLAMF3
in HCC retains RB factor in its hypophosphorylated active form, which in turn inactivates E2F transcription factor, thereby repressing the expression and activation of PLK1. A clear inverse correlation was also observed between
SLAMF3
and PLK expression in patients with HCC. In conclusion, the results presented here suggest that the tumor suppressor potential of
SLAMF3
occurs through activation of RB that represses PLK1. We propose that the induction of a high expression level of
SLAMF3
in cancerous cells could control cellular mitosis and block tumor progression.
...
PMID:RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. 2679 23